AstraZeneca and Bristol-Myers complete diabetes alliance expansion; Lilly revises guidance

10 August 2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that, following Bristol-Myers Squibb’s (NYSE: BMY) completion of the acquisition of Amylin Pharmaceuticals (The Pharma Letter July 2), it has made an initial payment of about $3.2 billion to Amylin, now a wholly-owned subsidiary of B-MS. The move also resulted in US drug major Eli Lilly (NYSE: LLY) to revise its guidance as a result of early payment of financial obligations to Amylin.

As previously disclosed, the payment is being made in connection with the expansion of the diabetes alliance between AstraZeneca and B-MS to incorporate the development and marketing of Amylin’s portfolio of diabetes products, and profits and losses arising from the collaboration will be shared equally.

AZ will exercise additional option

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK